Logo

Cadila Launches Cadalimab (biosimilar- adalimumab) in India

Share this

Cadila Launches Cadalimab (biosimilar- adalimumab) in India

Shots:

  • Cadila has launched the adalimumab biosimilar under the brand name Cadalimab- referencing AbbVie’s Humira which is used to treat RA-PsA- AS and psoriasis
  • The launch strengthens Cadila’s biosimilar portfolio as Cadalimab is the fourth biosimilar launched in the last 2mos. following Bevaro- Ritucad and NuPTH for cancer and osteoporosis
  • Cadalimab is available in 40mg/0.8ml- easy pre-filled syringe and has shown a significant reduction in signs and symptoms of many diseases including RA- JIA- AS and PsA

­ Ref: Cadila  | Image: Cadila

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions